| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| WARNER BROS DISCOVERY | 156 | 9 | +0,68 % | ||
| NETFLIX | 141 | 84 | +0,24 % | ||
| PARAMOUNT SKYDANCE | 134 | 21 | +3,97 % | ||
| ALPHABET | 125 | 698 | -0,26 % | ||
| NVIDIA | 121 | 219 | +1,13 % | ||
| APPLE | 74 | 642 | +0,08 % | ||
| IBM | 57 | 35 | +0,38 % | ||
| TESLA | 56 | 431 | -0,48 % | ||
| FORD MOTOR | 46 | 137 | -0,60 % | ||
| MICROSOFT | 43 | 451 | +0,11 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:12 | CVS Health Updates 2025 Guidance; Issues 2026 Outlook | 1 | AFX News | WOONSOCKET (dpa-AFX) - CVS Health (CVS) said, for 2025, it increased adjusted EPS guidance range to $6.60 to $6.70 from $6.55 to $6.65. The company raised adjusted operating income guidance... ► Artikel lesen | |
| 13:12 | Pfizer Inks About $2 Bln Exclusive Deal With Fosun's YaoPharma To For Novel GLP-1 Obesity Therapy | - | AFX News | NEW YORK CITY (dpa-AFX) - Pfizer, Inc. (PFE) announced Tuesday it has inked an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of global healthcare company... ► Artikel lesen | |
| 13:10 | BioNTech SE: BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer | 21 | GlobeNewswire (Europe) | Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer ("TNBC") show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy... ► Artikel lesen | |
| 13:10 | BioNTech SE: Erste Ergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs | 33 | GlobeNewswire (Deutschland) | Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, "TNBC") zeigten eine ermutigende Anti-Tumor-Aktivität... ► Artikel lesen | |
| 13:10 | Oracle's AI Cloud Surge: From Summer Glory to a Dip Worth Buying | - | Zacks | ||
| 13:10 | Starbucks workers are still without a labor deal four years after their first union win. Here's why | - | CNN | ||
| 13:10 | Walmart International Gains in Q3: Can the Upside Extend Into 2026? | - | Zacks | ||
| 13:09 | Doppelt knusprig: Amazon verkauft Luxus-Heißluftfritteuse zum Witzpreis | - | GIGA | ||
| 13:09 | "7 vs. Wild" Staffel 5: Wann ist die finale Folge 16 auf YouTube? | - | GIGA | ||
| 13:09 | AI Overview und KI-Modus: EU ermittelt gegen Googles KI-Suchmaschinen | - | ComputerBase | ||
| 13:09 | Googles KI-Antworten - EU ermittelt gegen US-Konzern | 23 | Moneycab | Brüssel - Die EU verdächtigt den US-Internetriesen Google, seine Künstliche Intelligenz rechtswidrig mit Online-Inhalten Dritter gefüttert zu haben. Die zuständige Europäische Kommission leitet daher... ► Artikel lesen | |
| 13:06 | AutoZone GAAP EPS of $31.04 misses by $1.36, revenue of $4.63B misses by $10M | 6 | Seeking Alpha | ||
| 13:06 | AerCap stock initiated with Buy rating at Truist on fleet strength | 3 | Investing.com | ||
| 13:06 | Micron stock initiated with Buy rating at HSBC on DRAM rally potential | 4 | Investing.com | ||
| 13:06 | IRIS Software Group Launches AI-powered Tax Anomaly Detection Tool Built on Microsoft Foundry | 46 | PR Newswire | New tool, which will be integrated into IRIS Elements and IRIS Accounting Suite for all customers, will reduce time to file a tax return from four hours to as little as 90 minutesAcross the... ► Artikel lesen | |
| 13:06 | HII Deepens Partnership with Babcock International Group in Support of Virginia-Class Submarine Construction | 2 | GlobeNewswire (USA) | ||
| 13:05 | CVS HEALTH - Prognoseerhöhung! | 2 | stock3.com | ||
| 13:00 | AutoZone, Inc.: AutoZone 1st Quarter Total Company Same Store Sales Increase 4.7%; Domestic Same Store Sales Increase 4.8%; 1st Quarter EPS of $31.04 | 6 | GlobeNewswire (USA) | ||
| 12:59 | CVS Health Updates 2025 Guidance; Issues 2026 Outlook | 2 | RTTNews | ||
| 12:59 | ASH: Jaypirca matches Imbruvica in first-line CLL trial | 2 | pharmaphorum |